Anhui Zhifei Longcom Biopharma · Recombinant Proteins · Recombinant Proteins
COVID-19 vaccine is a recombinant proteins developed by Anhui Zhifei Longcom Biopharma. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.
| Brand Names | ZF2001, Zifivax, ZF 2001 |
| Company | Anhui Zhifei Longcom Biopharma |
| Drug Class | Recombinant Proteins, Vaccine |
| Route | Injectable (Others), Intramuscular (IM) Injection |
| Status | Approved |
COVID-19 vaccine is developed for 1 unique indication across 1 therapeutic area.
| Therapeutic Area | Condition | Phase |
|---|---|---|
| Infections and infestations | COVID-19 | ✓ Approved |
Chawanpaiboon Saifon S, Anuwutnavin Sanitra S, Kanjanapongporn Attapol A, Pooliam Julaporn J et al.
Perry Bryce Nicole V NV, Marrero Arocho Maria De L ML, Seybold Dara D, Calhoun Byron B
To evaluate tetanus, diphtheria, and acellular pertussis (Tdap) vaccination rates among pregnant patients before, during, and after the COVID-19 pandemic and identify demographic and care-related factors associated with vaccine uptake at our tertiary-care medical center in Southern West Virginia. We conducted a retrospective cohort study of pregnant patients age 18 years or older with viable pregnancies through 36 weeks of gestation from January 11, 2019, to June 30, 2024 at a single tertiary-care medical center. Patients were categorized into pre-COVID-19, during-COVID-19, and post-COVID-19 cohorts. Vaccination uptake was analyzed using ANOVA, and additional bivariate analyses were conducted to identify demographic and clinical factors associated with Tdap receipt during pregnancy. Among 2513 patients, 1705 (67.8%) received Tdap vaccination, which was higher than the national average of 56.6% in 2022-2023. Vaccination rates did not differ across 3 different phases relative to the COVID-19 pandemic (p = .97). Tdap vaccination was more common among patients who were married as compared with unmarried patients (70.4% vs 65.8%, p = .016), white versus non-white patients (68.9% vs 62.5%, p = .011), and patients receiving care in private-practice-based clinics versus hospital-based clinics (76.6% vs 65.6%, p < .001). No statistically significant difference was noted when stratified by insurance type (p = .24) or advanced maternal age (≥35 years) (p = .35). Tdap vaccination rates at our institution exceeded national averages and remained stable throughout the COVID-19 pandemic. Persistent disparities by race, marital status, and care setting highlight vaccination inequities and support the need for targeted interventions for patient and provider sub-groups.
Bibi Walid K WK, Mohanty Avha R AR, Tatara Alexander M AM
The Coronavirus Disease of 2019 (COVID-19) pandemic caused by SARS-CoV-2 resulted in widespread mortality, economic strain, and healthcare system disruption, highlighting the need for effective strategies to address viral threats. Tissue engineering and biomaterials can contribute significantly in advancing our understanding and treatment of respiratory viral infections by developing physiologically relevant in vitro models, controlled and targeted drug delivery systems, and effective next-generation vaccine platforms. Over the last 5 years, tissue-engineered cell-based models, including organ-on-a-chip systems, have improved our understanding of viral entry, immune response, and therapeutic efficacy in pulmonary, cardiac, neurological, and vascular tissue. Biomaterial-based delivery systems have enhanced the targeting, bioavailability, and sustained delivery of therapeutics such as antivirals, monoclonal antibodies, nucleic-acid-based vaccines, and anti-inflammatory drugs, while also reducing or eliminating system toxicity and our reliance on intravenous administration. Advancements in vaccine platforms using lipid nanoparticles, protein scaffolds, and vesicular or cell-based platforms are in different phases of development to stimulate more robust responses against emerging SARS-CoV-2 variants. Collectively, these advancements highlight the influence of tissue engineering and biomaterials in SARS-CoV-2 research and treatment. This review provides an overview of recent developments in in vitro modeling, drug delivery systems, and vaccine platforms, highlighting their future role in improving clinical outcomes, managing variants, and preparing for potential future pandemics, including addressing challenges in infrastructure such as limited access to high-containment biosafety facilities used to study emerging infectious pathogens.Impact StatementDuring the COVID-19 pandemic, we introduced basic tenets of virology to a tissue engineering audience and proposed different areas in which the field could contribute to developing diagnostics and therapeutics for respiratory viral infections. In this 5-year update, we highlight how tissue engineers and biomaterial scientists contributed tools to dissect virus pathophysiology and deliver therapies such as mRNA vaccines to prevent mortality during the pandemic. With the emergence of new variants and the threat of new respiratory viral pandemics, tissue engineers can continue to play important roles in virology.
Qu Yafei Y, Zhou Jinglin J, Wang Xinjia X, Dong Shupeng S et al.
Cengi̇z Mehmet M, Cengi̇z Şefika Nurhüda Karaca ŞNK, Büyükcam Ayşe A, Bolat Ahmet A et al.
The Coronavirus Disease 2019 (COVID-19) pandemic has substantially disrupted the lives of children and adolescents, raising concerns about increased psychiatric morbidity. This study examined post-COVID psychiatric symptoms in a pediatric population and explored associated risk factors. This follow-up study enrolled 107 children and adolescents (6-18 years) with laboratory-confirmed COVID-19, retrospectively identified from Gülhane Training and Research Hospital records, contacted via telephone, and invited for in-person pediatric examination and Revised Child Anxiety and Depression Scale (RCADS) screening. Participants with T-scores ≥65 were referred to Gazi University for face-to-face psychiatric evaluation by child psychiatrists using DSM-5 criteria. Sociodemographic and clinical variables were analyzed for associations with elevated RCADS scores. Receiver operating characteristic (ROC) analyses were performed using DSM-5-based clinical diagnoses as the reference standard. The cohort included 62 females (57.9%) and 45 males (42.1%), with a mean age of 12.3±3.1 years. Most participants were symptomatic during infection (90.7%), and 35.5% developed at least one COVID-related complication, most commonly taste loss (29.0%). Post-COVID psychiatric symptoms were reported in 56.1% of cases, predominantly attention difficulties (28.9%) and irritability (23.3%). Approximately half (52.2%) of children without prior history of psychiatric symptoms developed at least one new symptom. Higher anxiety and depression scores were significantly associated with prematurity, birth complications, and pre-existing psychiatric symptoms. In ROC analyses, the parent-reported total anxiety score showed an area under the curve (AUC) of 0.92 with an optimal cut-off of 60 (sensitivity 81.5%, specificity 93.8%), while the child-reported score showed an AUC of 0.90 with an optimal cut-off of 65 (sensitivity 70.4%, specificity 93.8%). Children without psychiatric history had significantly lower scores (p < 0.001). COVID-19 was linked to increased psychiatric symptoms in children, with prematurity, birth complications, and prior history as key risks. RCADS proved sensitive for screening, emphasizing targeted interventions post-infection. Not applicable.
Flegg Carolyn C, Barczak Aleksandra A, Fienberg Samantha S, Fleming Rachel R et al.
Axillary lymphadenopathy following vaccination has long been recognized as a benign, self-limited immune response, but its increased frequency during the COVID 19 vaccination campaign created diagnostic uncertainty and contributed to delays in breast imaging and unnecessary follow-up. Early conservative guidance, issued in the context of limited evidence, led to postponed screening examinations and increased patient anxiety. Since then, robust prospective and longitudinal data have demonstrated an extremely low, near-zero risk of malignancy in asymptomatic patients with isolated ipsilateral axillary lymphadenopathy following recent COVID 19 vaccination and no suspicious breast imaging findings, even when lymphadenopathy persists for many months. In response to this evolving evidence base, the Canadian Association of Radiologists (CAR) and Breast Radiologists of Canada (BRC) have developed updated, evidence-based recommendations for the management of axillary lymphadenopathy following COVID 19 vaccination. These recommendations emphasize that breast imaging examinations should not be delayed because of vaccination, outline the importance of documenting vaccination history, and provide clear guidance for classifying and managing ipsilateral, contralateral, palpable, and persistent lymphadenopathy across breast imaging modalities. Special considerations for patients with a personal history of breast cancer or other malignancies are also addressed. Adoption of these recommendations is intended to promote consistent national practice, reduce unnecessary imaging and biopsy, support patient reassurance, and maintain the effectiveness of breast cancer screening programs.
+9996 more articles available with a free account
Sign up free to view all articles →